Johnson Fistel launches probe into Simulations Plus after $90M-$93M guidance cut
SLP•Simulations Plus faces an investor probe by law firm Johnson Fistel following a downward revision of its full-year revenue guidance from $90M-$93M. Analysts’ consensus price target remains $18.50 despite new accounting disclosures and rising concerns over potential investor losses.
1. Revenue Guidance Cut
On July 8, 2026, Simulations Plus reduced its 2026 revenue guidance, retracting the previous full-year target of $90 million to $93 million to a lower range. This revision follows the second-quarter results released April 3, highlighting softer demand for its pharmaceutical software solutions.
2. Investor Investigation
Law firm Johnson Fistel has opened an investor investigation into Simulations Plus to assess whether the company’s public statements and new accounting disclosures misled shareholders, resulting in financial losses. The probe will examine potential violations of federal securities laws related to the guidance change.
3. Analyst Expectations
Despite the guidance cut and legal scrutiny, analysts have maintained a consensus price target of $18.50 for Simulations Plus shares. This stability reflects continued confidence in the company’s AI-driven drug development modeling products like GastroPlus and DDDPlus.
